Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach
- 12 May 2020
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 318 (6), L1239-L1243
- https://doi.org/10.1152/ajplung.00161.2020
Abstract
Lethality of coronavirus disease (COVID-19) during the 2020 pandemic, currently still in the exponentially accelerating phase in most countries, is critically driven by disruption of the alveolo-capillary barrier of the lung, leading to lung edema as a direct consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We argue for inhibition of the transient receptor potential vanilloid 4 (TRPV4) calcium-permeable ion channel as a strategy to address this issue, based on the rationale that TRPV4 inhibition is protective in various preclinical models of lung edema and that TRPV4 hyperactivation potently damages the alveolo-capillary barrier, with lethal outcome. We believe that TRPV4 inhibition has a powerful prospect at protecting this vital barrier in COVID-19 patients, even to rescue a damaged barrier. A clinical trial using a selective TRPV4 inhibitor demonstrated a benign safety profile in healthy volunteers and in patients suffering from cardiogenic lung edema. We argue for expeditious clinical testing of this inhibitor in COVID-19 patients with respiratory malfunction and at risk for lung edema. Perplexingly, among the currently pursued therapeutic strategies against COVID-19, none is designed to directly protect the alveolo-capillary barrier. Successful protection of the alveolo-capillary barrier will not only reduce COVID-19 lethality but will also preempt a distressing healthcare scenario with insufficient capacity to provide ventilator-assisted respiration.Keywords
Funding Information
- HHS | NIH | National Institute of Environmental Health Sciences (U01ES015674)
This publication has 48 references indexed in Scilit:
- TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injuryAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2014
- An Orally Active TRPV4 Channel Blocker Prevents and Resolves Pulmonary Edema Induced by Heart FailureScience Translational Medicine, 2012
- A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip MicrodeviceScience Translational Medicine, 2012
- TRPV4 channels augment macrophage activation and ventilator-induced lung injuryAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2010
- Systemic Activation of the Transient Receptor Potential Vanilloid Subtype 4 Channel Causes Endothelial Failure and Circulatory Collapse: Part 2The Journal of pharmacology and experimental therapeutics, 2008
- Negative-Feedback Loop Attenuates Hydrostatic Lung Edema via a cGMP-Dependent Regulation of Transient Receptor Potential Vanilloid 4Circulation Research, 2008
- TRPV4 initiates the acute calcium-dependent permeability increase during ventilator-induced lung injury in isolated mouse lungsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- Radiology of Severe Acute Respiratory Syndrome (SARS)Journal of Thoracic Imaging, 2006
- Transient Receptor Potential Vanilloid 4–Mediated Disruption of the Alveolar Septal BarrierCirculation Research, 2006
- Pulmonary pathology of severe acute respiratory syndrome in TorontoLaboratory Investigation, 2005